Quanta System Q-Plus C EVO
Q-Switched Tattoo/Pigment · QS Nd:YAG + ruby (+alex option)
Technology: Nd:YAG Laser
Classification & configurations
Category group: Resurfacing & pigment (ablative, fractional, picosecond, vascular)
At a glance
- New price
- $80k–$110kSource not documented
- Used asking price
- $45k–$70kSource not documented
- FDA status
- Supplies & recurring costs
- Supply details not yet documented.
Sources and verified data on file
Data on file
- Recurring consumables
- Not verified
- Used asking prices
- Not verified
- This panel shows a per-treatment supply cost only when a recorded figure has a dated source.
- Bottle prices and estimates may still appear under Treatment & running costs.
- The calculator may include a labeled planning estimate. Review it or enter your own allowance; missing data never means $0.
Figures are reference points, not current offers. Used asking prices are not completed-sale values.
Read FDA-cleared indicationsExact wording from 3 FDA records
K152012 (Quanta System Spa, 2015)
The EVO Platform is intended for use in aesthetic, cosmetic and surgical applications requiring incision, excision, ablation, vaporization and coagulation of body soft tissues in the medical specialties of dermatology, general, plastic and oral surgery as follows. 1064 & 532 nm (Q-Switched, nanosecond mode) The EVO Platform is intended for treatment of vascular lesions, pigmented lesions, and for hair, tattoo removal and the incision, excision, ablation, vaporization of soft tissue for General dermatology such as, but not limited to treatment of: 532 nm (Q-Switched, nanosecond mode) Removal of light ink (red, sky blue, green, tan, purple, and orange) tattoos Treatment of vascular lesions including, but not limited to: - port wine birthmarks - telangiectasias - spider angiomaa - Cherry angioma - Spider nevi Treatment of benign pigmented lesions including, but not limited to: - cafe-au-Iait birthmarks - Ephalides, solar lentigines - senile lentigines - Becker's nevi - freckles - common nevi - nevus spilus - Ota Nevus Treatment of seborrheic keratosis Treatment of post inflammatory hyperpigmentation Skin resurfacing procedures for the treatment of acne scars and wrinkles.
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
K160368 (Quanta System Spa, 2016)
The EVO Platform is intended for use in aesthetic, cosmetic and surgical applications requiring incision, excision, ablation, vaporization and coagulation of body soft tissues in the medical specialties of dermatology, general, plastic and oral surgery as follows. 1064 & 532 nm (Q-Switched, nanosecond mode): The EVO Platform is intended for treatment of vascular lesions, pigmented lesions, and for hair, tattoo removal and the incision, excision, ablation, vaporization of soft tissue for General dermatology such as, but not limited to treatment of: 532 nm (Q-Switched, nanosecond mode): • Removal of light ink (red, sky blue, green, tan, purple, and orange) tattoos • Treatment of vascular lesions including, but not limited to: port wine birthmarks; telangiectasias; spider angioma; Cherry angioma; Spider nevi • Treatment of benign pigmented lesions including, but not limited to: cafe-au-lait birthmarks; Ephalides, solar lentigines; senile lentigines; Becker's nevi; freckles; common nevi; nevus spilus; Ota Nevus • Treatment of seborrheic keratosis • Treatment of post inflammatory hyperpigmentation • Skin resurfacing procedures for the treatment of acne scars and wrinkles. […]
Excerpt — verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026; "[…]" marks text omitted from the source.
K192160 (Quanta System Spa, 2019)
The EVO Platform is intended for use in aesthetic, cosmetic and surgical applications requiring incision, excision, ablation, vaporization and coagulation of body soft tissues in the medical specialties of dermatology, general, plastic and oral surgery as follows. 1064 & 532 nm (Q-Switched, nanosecond mode) The EVO Platform is intended for treatment of vascular lesions, pigmented lesions, and for hair, tattoo removal and the incision, excision, ablation, vaporization of soft tissue for General dermatology such as, but not limited to treatment of: 532 nm (Q-Switched, nanosecond mode) Removal of light ink (red, sky blue, green, tan, purple, and orange) tattoos Treatment of vascular lesions including, but not limited to: - port wine birthmarks - telangiectasias - spider angiomaa - Cherry angioma - Spider nevi Treatment of benign pigmented lesions including, but not limited to: - cafe-au-Iait birthmarks - Ephalides, solar lentigines - senile lentigines - Becker's nevi - freckles - common nevi - nevus spilus - Ota Nevus Treatment of seborrheic keratosis Treatment of post inflammatory hyperpigmentation Skin resurfacing procedures for the treatment of acne scars and wrinkles.
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
Page updated: September 8, 2026 · How we verify
Axis runs $0–$110k. Reference figures, not current offers. Used asking prices are not completed-sale values.
Not verified
We hold no per-treatment consumable price for this device from a dated source. Ask the seller for a written per-treatment cost.
Price sourcesSources, dates and configurations
Key factsCompany, specifications and verification dates
| Manufacturer | Quanta System |
|---|---|
| Company | Owner: El.En. Group S.p.A. (Euronext Milan: ELN), 100% (subsidiary, since 2012) · Distribution: via distributor — Astanza Laser (exclusive US distributor from December 1, 2025; previously Cartessa Aesthetics) |
| Parent company | El.En. Group |
| Brand owner | Quanta System |
| Built by (OEM) | Quanta System S.p.A. |
| Category | Q-Switched Tattoo/Pigment |
| Technology | QS Nd:YAG + ruby (+alex option) |
| FDA status | FDA Cleared |
| 510(k) citation | K152012, K160368, K192160 |
| New price range | $80k–$110k |
| Used asking range | $45k–$70k |
| Consumables | Not published |
| Launch year | 2019 |
| Pricing | Not published |
| Manufacturer-source documents checked | Not published |
Overview
Updated EVO series Q-Plus
FDA & regulatory detailClearance timeline, authorization route and citation notes
Family/platform clearance: K152012 (EVO Platform — Q-switched/pulsed Nd:YAG 532/1064/1320 nm, ruby 694 nm and alexandrite 755 nm sources, decision 8 Dec 2015), K160368 (5 Apr 2016) and K192160 (6 Sep 2019); no 510(k) naming Q-Plus C EVO was located. Checked 8 Sep 2026.
FDA-cleared indications (verbatim)
K152012 (Quanta System Spa, 2015)
The EVO Platform is intended for use in aesthetic, cosmetic and surgical applications requiring incision, excision, ablation, vaporization and coagulation of body soft tissues in the medical specialties of dermatology, general, plastic and oral surgery as follows. 1064 & 532 nm (Q-Switched, nanosecond mode) The EVO Platform is intended for treatment of vascular lesions, pigmented lesions, and for hair, tattoo removal and the incision, excision, ablation, vaporization of soft tissue for General dermatology such as, but not limited to treatment of: 532 nm (Q-Switched, nanosecond mode) Removal of light ink (red, sky blue, green, tan, purple, and orange) tattoos Treatment of vascular lesions including, but not limited to: - port wine birthmarks - telangiectasias - spider angiomaa - Cherry angioma - Spider nevi Treatment of benign pigmented lesions including, but not limited to: - cafe-au-Iait birthmarks - Ephalides, solar lentigines - senile lentigines - Becker's nevi - freckles - common nevi - nevus spilus - Ota Nevus Treatment of seborrheic keratosis Treatment of post inflammatory hyperpigmentation Skin resurfacing procedures for the treatment of acne scars and wrinkles.
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
K160368 (Quanta System Spa, 2016)
The EVO Platform is intended for use in aesthetic, cosmetic and surgical applications requiring incision, excision, ablation, vaporization and coagulation of body soft tissues in the medical specialties of dermatology, general, plastic and oral surgery as follows. 1064 & 532 nm (Q-Switched, nanosecond mode): The EVO Platform is intended for treatment of vascular lesions, pigmented lesions, and for hair, tattoo removal and the incision, excision, ablation, vaporization of soft tissue for General dermatology such as, but not limited to treatment of: 532 nm (Q-Switched, nanosecond mode): • Removal of light ink (red, sky blue, green, tan, purple, and orange) tattoos • Treatment of vascular lesions including, but not limited to: port wine birthmarks; telangiectasias; spider angioma; Cherry angioma; Spider nevi • Treatment of benign pigmented lesions including, but not limited to: cafe-au-lait birthmarks; Ephalides, solar lentigines; senile lentigines; Becker's nevi; freckles; common nevi; nevus spilus; Ota Nevus • Treatment of seborrheic keratosis • Treatment of post inflammatory hyperpigmentation • Skin resurfacing procedures for the treatment of acne scars and wrinkles. […]
Excerpt — verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026; "[…]" marks text omitted from the source.
K192160 (Quanta System Spa, 2019)
The EVO Platform is intended for use in aesthetic, cosmetic and surgical applications requiring incision, excision, ablation, vaporization and coagulation of body soft tissues in the medical specialties of dermatology, general, plastic and oral surgery as follows. 1064 & 532 nm (Q-Switched, nanosecond mode) The EVO Platform is intended for treatment of vascular lesions, pigmented lesions, and for hair, tattoo removal and the incision, excision, ablation, vaporization of soft tissue for General dermatology such as, but not limited to treatment of: 532 nm (Q-Switched, nanosecond mode) Removal of light ink (red, sky blue, green, tan, purple, and orange) tattoos Treatment of vascular lesions including, but not limited to: - port wine birthmarks - telangiectasias - spider angiomaa - Cherry angioma - Spider nevi Treatment of benign pigmented lesions including, but not limited to: - cafe-au-Iait birthmarks - Ephalides, solar lentigines - senile lentigines - Becker's nevi - freckles - common nevi - nevus spilus - Ota Nevus Treatment of seborrheic keratosis Treatment of post inflammatory hyperpigmentation Skin resurfacing procedures for the treatment of acne scars and wrinkles.
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
Marketed for
Nd:YAG — QS Nd:YAG + ruby (+alex option)
Marketing claims are the manufacturer's own and are not the same as a cleared indication.
Parent company: El.En. Group
Legal manufacturer: Quanta System S.p.A. (Italy)
Applicant on the FDA record
Quanta System S.p.A.The applicant named on the FDA record can differ from the brand shown on the device.
Regulatory data comes from public FDA records and may lag recent updates. Confirm the applicable status and documentation before purchase.
Treatment & running costs
Treatments
Sessions & timing
No treatment schedule documented yet.
What practices charge
No sourced treatment price on file.
Supplies & recurring costs
Consumable costs are not documented yet.
Annual service & support
No annual service cost documented yet.
Payback calculatorModel your own volume, labor and service costs
Estimate your payback
Pre-filled from our published Quanta System Q-Plus C EVO data where we have it. Estimates appear once the required inputs are available. Review and adjust every pre-filled value before relying on the result.
Start from
No verified per-treatment supply cost is on file. Enter your own allowance. Use $0 only if you have confirmed that it applies to your practice.
Pre-filled from the midpoint of the published new-price range
20 is an illustrative default — change it to your volume.
No sourced per-session price on file — enter what you charge.
Required — enter your cost; missing data does not mean $0.
Provider or tech time for one treatment, fully loaded. Enter 0 if you own-operate.
Annual service contract ÷ 12, if you carry one.
Your estimate
Enter price you charge per treatment, consumable cost per treatment to see contribution and a payback range.
This model ignores financing — if you lease or borrow, add your monthly payment. Estimates from your inputs and our published ranges — not a projection, guarantee or financial advice. How we calculate this.
Warranty & serviceWhat to confirm in writing before you buy
Before buying new or used, confirm in writing:
- Current warranty coverage
- Included training
- Service terms
Chains using this device
A chain listing does not establish availability at every location.
No confirmed chain deployments recorded yet.
Owner & operator reviews
Write a reviewNo owner or operator reviews yet. Be the first →
Current alternatives
Current catalog models to research. Confirm availability and configuration with the supplier.
History4 tracked changes
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
September 8, 2026
FDA status
Unknown → Cleared
Source: Record correction
September 8, 2026
FDA K-numbers
K152012; K160368; K192160
Source: Record correction
September 8, 2026
FDA source URL
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K152012
Source: Record correction
August 1, 2026
Record created
Added to The Aesthetic Index — August 2026
Source: The Aesthetic Index editorial
Cite this data: The Aesthetic Index, "Quanta System Q-Plus C EVO — pricing, FDA status and cost to own", aestheticindex.co (accessed September 24, 2026).
Get the full State of Aesthetic Devices 2026 report
A catalog of US-marketed aesthetic and wellness devices — preview it free.
Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.